Trial Outcomes & Findings for Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs (NCT NCT02592707)

NCT ID: NCT02592707

Last Updated: 2023-07-19

Results Overview

AE is defined as any untoward medical occurrence in a subject or clinical trial subject administered a medicinal product, which did not necessarily have a causal relationship with this treatment. A serious AE (SAE) was classified as any untoward medical occurrence that at any dose results in death; AE was life threatening; required inpatient hospitalization or prolonged existing hospitalization; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect; was an important medical event that may not result in death. TEAEs are defined as AEs that developed or worsened after start of treatment.

• Recruitment status: TERMINATED
• Study phase: PHASE1/PHASE2
• Target enrollment: 40 participants
• Primary outcome timeframe: From the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, maximum of 33 months
• Results posted on: 2023-07-19

Participant Flow

This Phase 1/2, open-label study was conducted in participants with somatostatin receptor positive neuroendocrine tumour (NETs) at 8 investigational sites in Australia, Austria, Canada, Denmark, France, Switzerland and United Kingdom between 06 March 2017 and 22 February 2022. The sponsor terminated the study early for strategic reasons and this decision was not due to any safety or tolerability concern of the study drug.

The study was performed in 2 parts, Part A and Part B. Study consists of a screening period (up to 4 weeks), Treatment period (3 core treatment cycles in each Part A and Part B; 2 additional cycles in Part B only) and followed by long-term follow-up (LTFU) period (2 years). Each cycle was 8 weeks (+ up to 4 weeks if toxicity) apart. A total 40 participants were treated in this study. Due to initial findings, Cohorts 2, 4, 5, 7 and 8 in Part B were not performed in this study.

Participant milestones

Measure	Part A: 177Lu-IPN01072 4.5 GBq Participants received 4.5 gigabecquerel (GBq) 177Lu-IPN01072 \[target dose of 300 microgram (mcg) ±50 mcg\] intravenous (IV) infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart \[+2 weeks or up to +4 weeks in case of adverse events (AE) which had not adequately recovered\].	Part B Cohort 1: 177Lu-IPN01072 6 GBq Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by data review board (DRB). As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).
Overall Study STARTED	15	6	9	10
Overall Study COMPLETED	9	1	3	3
Overall Study NOT COMPLETED	6	5	6	7

Reasons for withdrawal

Measure	Part A: 177Lu-IPN01072 4.5 GBq Participants received 4.5 gigabecquerel (GBq) 177Lu-IPN01072 \[target dose of 300 microgram (mcg) ±50 mcg\] intravenous (IV) infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart \[+2 weeks or up to +4 weeks in case of adverse events (AE) which had not adequately recovered\].	Part B Cohort 1: 177Lu-IPN01072 6 GBq Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by data review board (DRB). As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).
Overall Study Consent Withdrawn	0	1	2	0
Overall Study Death	1	0	0	0
Overall Study Progressive Disease	4	4	3	3
Overall Study Other	0	0	1	2
Overall Study Never entered LTFU period	1	0	0	2

Baseline Characteristics

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Baseline characteristics by cohort

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=15 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=6 Participants Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=9 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=10 Participants Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Total n=40 Participants Total of all reporting groups
Age, Continuous	62.7 years STANDARD_DEVIATION 12.9 • n=5 Participants	65.3 years STANDARD_DEVIATION 8.9 • n=7 Participants	55.0 years STANDARD_DEVIATION 16.0 • n=5 Participants	56.7 years STANDARD_DEVIATION 13.7 • n=4 Participants	59.9 years STANDARD_DEVIATION 13.5 • n=21 Participants
Age, Customized <65	7 Participants n=5 Participants	3 Participants n=7 Participants	6 Participants n=5 Participants	7 Participants n=4 Participants	23 Participants n=21 Participants
Age, Customized >=65	8 Participants n=5 Participants	3 Participants n=7 Participants	3 Participants n=5 Participants	3 Participants n=4 Participants	17 Participants n=21 Participants
Sex: Female, Male Female	8 Participants n=5 Participants	2 Participants n=7 Participants	3 Participants n=5 Participants	6 Participants n=4 Participants	19 Participants n=21 Participants
Sex: Female, Male Male	7 Participants n=5 Participants	4 Participants n=7 Participants	6 Participants n=5 Participants	4 Participants n=4 Participants	21 Participants n=21 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	15 Participants n=5 Participants	6 Participants n=7 Participants	9 Participants n=5 Participants	10 Participants n=4 Participants	40 Participants n=21 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants
Race/Ethnicity, Customized Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants
Race/Ethnicity, Customized Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants
Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants
Race/Ethnicity, Customized White	15 Participants n=5 Participants	6 Participants n=7 Participants	9 Participants n=5 Participants	9 Participants n=4 Participants	39 Participants n=21 Participants
Race/Ethnicity, Customized Other	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants

PRIMARY outcome

Timeframe: From the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, maximum of 33 months

Population: The SAS included all participants who received 177Lu-IPN01072.

AE is defined as any untoward medical occurrence in a subject or clinical trial subject administered a medicinal product, which did not necessarily have a causal relationship with this treatment. A serious AE (SAE) was classified as any untoward medical occurrence that at any dose results in death; AE was life threatening; required inpatient hospitalization or prolonged existing hospitalization; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect; was an important medical event that may not result in death. TEAEs are defined as AEs that developed or worsened after start of treatment.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=15 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=6 Participants Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=9 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=10 Participants Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants n=40 Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs TEAEs	15 Participants	6 Participants	9 Participants	10 Participants	40 Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs Serious TEAEs	2 Participants	1 Participants	2 Participants	3 Participants	8 Participants

PRIMARY outcome

Timeframe: From the start of the first study medication (Cycle 1 Day 1) up to EOCT, maximum of 16 weeks.

Population: The SAS included all participants who received 177Lu-IPN01072.

DLTs were defined as study medication-related AEs with a severity of Grade 3 or higher are considered DLT, with the exception of hair loss, lymphopenia, nonfebrile neutropenia lasting <4 weeks and thrombocytopenia lasting <4 weeks.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=15 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=6 Participants Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=9 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=10 Participants Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants n=40 Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Number of Participants With Dose Limiting Toxicities (DLT)	3 Participants	0 Participants	2 Participants	1 Participants	6 Participants

SECONDARY outcome

Timeframe: 4, 24, 48, 72 to 96 hours, 144 to 168 hours post infusion in Cycle 1

Population: The Per Protocol Dosimetry Analysis Set (PP-DAS) included all participants in the Intent-To-Treat Dosimetry Analysis Set (ITT-DAS) for whom no major protocol violations occurred affecting dosimetry variables. Only data from the participants analyzed were reported.

177Lu-IPN01072 uptake in organs and lesions was evaluated centrally, using nuclear medicine images, as part of the dosimetry workflow. Uptake activity for organs of interest (i.e., body, bone marrow, kidney [left + right], healthy liver, and spleen) was determined. The maximal uptake in lesions was calculated for each lesion as: maximal activity divided injected activity*100.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=11 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=6 Participants Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=9 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=10 Participants Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants n=36 Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Maximum Uptake (%) of 177Lu-IPN01072 at Target Lesions and Discernible Organs in Cycle 1 Bone marrow (image-based)	0.0469 percentage of injected drug activity Interval 0.0246 to 0.0751	0.0420 percentage of injected drug activity Interval 0.01 to 0.28	0.0250 percentage of injected drug activity Interval 0.0149 to 0.057	0.0219 percentage of injected drug activity Interval 0.0053 to 0.03	0.0380 percentage of injected drug activity Interval 0.0053 to 0.28
Maximum Uptake (%) of 177Lu-IPN01072 at Target Lesions and Discernible Organs in Cycle 1 Liver	1.52 percentage of injected drug activity Interval 0.314 to 6.34	4.31 percentage of injected drug activity Interval 4.31 to 4.31	—	—	2.63 percentage of injected drug activity Interval 0.314 to 6.34
Maximum Uptake (%) of 177Lu-IPN01072 at Target Lesions and Discernible Organs in Cycle 1 Kidney (left + right)	1.96 percentage of injected drug activity Interval 0.98 to 3.82	1.76 percentage of injected drug activity Interval 1.05 to 2.08	1.60 percentage of injected drug activity Interval 1.19 to 2.51	1.67 percentage of injected drug activity Interval 0.749 to 2.41	1.76 percentage of injected drug activity Interval 0.749 to 3.82
Maximum Uptake (%) of 177Lu-IPN01072 at Target Lesions and Discernible Organs in Cycle 1 Spleen	1.50 percentage of injected drug activity Interval 0.274 to 2.93	1.27 percentage of injected drug activity Interval 0.96 to 2.46	1.78 percentage of injected drug activity Interval 0.55 to 5.97	1.79 percentage of injected drug activity Interval 1.19 to 2.65	1.67 percentage of injected drug activity Interval 0.274 to 5.97
Maximum Uptake (%) of 177Lu-IPN01072 at Target Lesions and Discernible Organs in Cycle 1 All lesions	0.651 percentage of injected drug activity Interval 0.029 to 6.35	2.36 percentage of injected drug activity Interval 0.266 to 8.74	1.18 percentage of injected drug activity Interval 0.235 to 18.7	1.43 percentage of injected drug activity Interval 0.19 to 15.0	0.932 percentage of injected drug activity Interval 0.029 to 18.7

SECONDARY outcome

Timeframe: Pre-infusion (Baseline), 5 and 30 minutes, 1, 4, 24, 48, 72 to 96 hours, 144 to 168 hours post infusion in Cycle 1

Population: The radiopharmaceutical pharmacokinetic (PK) set included all participants in the ITT set who received at least 1 dose of study medication and had at least 1 measured radioactive concentration in blood. Only data from the participants analyzed were reported.

177Lu-IPN01072 uptake in blood was evaluated on site/locally using a gamma counter calibrated for 177Lu-IPN01072 according to the dosimetry operational manual.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=13 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=6 Participants Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=8 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=10 Participants Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants n=37 Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Maximal Uptake (%) of 177Lu-IPN01072 in Blood in Cycle 1	3.66 percentage/liter (L) Interval 2.17 to 7.88	2.98 percentage/liter (L) Interval 2.26 to 4.35	2.77 percentage/liter (L) Interval 1.98 to 7.35	3.32 percentage/liter (L) Interval 0.539 to 4.11	3.03 percentage/liter (L) Interval 0.539 to 7.88

SECONDARY outcome

Timeframe: 4, 24, 48, 72 to 96 hours, 144 to 168 hours post infusion in Cycle 1

Population: The PP-DAS included all participants in the ITT-DAS for whom no major protocol violations occurred affecting dosimetry variables. Only data from the participants analyzed were reported.

The AUC of 177Lu-IPN01072 radioactivity in discernible organs were computed for each administration of 177Lu-IPN01072.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=11 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=6 Participants Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=9 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=10 Participants Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants n=36 Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Area Under the Concentration Time Curve (AUC) of 177Lu-IPN01072 in Discernible Organs in Cycle 1 Bone marrow (Image-based)	174 MBq*hour Interval 45.3 to 224.0	352 MBq*hour Interval 154.0 to 3988.0	138 MBq*hour Interval 91.0 to 362.0	157 MBq*hour Interval 41.5 to 244.0	175 MBq*hour Interval 41.5 to 3988.0
Area Under the Concentration Time Curve (AUC) of 177Lu-IPN01072 in Discernible Organs in Cycle 1 Kidney (left + right)	9596 MBq*hour Interval 3896.0 to 26596.0	8966 MBq*hour Interval 7350.0 to 10586.0	6239 MBq*hour Interval 5853.0 to 11269.0	7578 MBq*hour Interval 3320.0 to 9815.0	8239 MBq*hour Interval 3320.0 to 26596.0
Area Under the Concentration Time Curve (AUC) of 177Lu-IPN01072 in Discernible Organs in Cycle 1 Liver	6745 MBq*hour Interval 755.0 to 20751.0	17918 MBq*hour Interval 17918.0 to 17918.0	—	—	11133 MBq*hour Interval 755.0 to 20751.0
Area Under the Concentration Time Curve (AUC) of 177Lu-IPN01072 in Discernible Organs in Cycle 1 Spleen	6701 MBq*hour Interval 1134.0 to 21451.0	7949 MBq*hour Interval 4945.0 to 11734.0	7727 MBq*hour Interval 1547.0 to 28269.0	8179 MBq*hour Interval 3901.0 to 12355.0	7772 MBq*hour Interval 1134.0 to 28269.0

SECONDARY outcome

Timeframe: Pre-infusion (Baseline), 5 and 30 minutes, 1, 4, 24, 48, 72 to 96 hours, 144 to 168 hours post infusion in Cycle 1

Population: The radiopharmaceutical PK set included all participants in the ITT set who received at least 1 dose of study medication and had at least 1 measured radioactive concentration in blood. Only data from the participants analyzed were reported.

The AUC of 177Lu-IPN01072 radioactivity in blood were computed for each administration of 177Lu-IPN01072.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=13 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=6 Participants Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=8 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=10 Participants Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants n=37 Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
AUC of 177Lu-IPN01072 in Blood in Cycle 1	623 MBq*hour/L Interval 299.0 to 1003.0	901 MBq*hour/L Interval 442.0 to 1806.0	690 MBq*hour/L Interval 371.0 to 1201.0	720 MBq*hour/L Interval 290.0 to 1034.0	726 MBq*hour/L Interval 290.0 to 1806.0

SECONDARY outcome

Timeframe: Pre-infusion (Baseline), 5 and 30 minutes, 1, 4, 24, 48, 72 to 96 hours, 144 to 168 hours post infusion in Cycle 1

Population: The radiopharmaceutical PK set included all participants in the ITT set who received at least 1 dose of study medication and had at least 1 measured radioactive concentration in blood. Only data from the participants analyzed were reported.

The terminal half-life was defined as the largest half-life of the decay curve of blood activity.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=13 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=6 Participants Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=8 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=10 Participants Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants n=37 Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Terminal Half-Life (T1/2) of Radioactivity Concentrations of the Radiopharmaceutical in Blood in Cycle 1	68.3 hours Interval 42.2 to 160.0	109 hours Interval 38.6 to 160.0	123 hours Interval 41.2 to 160.0	145 hours Interval 55.3 to 160.0	127 hours Interval 38.6 to 160.0

SECONDARY outcome

Timeframe: 4, 24, 48, 72 to 96 and 144 to 168 hours post infusion in Cycle 1

Population: The PP-DAS included all participants in the ITT-DAS for whom no major protocol violations occurred affecting dosimetry variables. Only data from the participants analyzed were reported.

The absorbed dose to the discernible organs (i.e., organs showing uptake) was evaluated centrally, using nuclear medicine images, as part of the dosimetry workflow. The organs considered for 177LU-IPN01072 image-based dosimetry assessment included: liver, bone marrow, kidney (left + right), and spleen. Highest absorbed dose of 177Lu-IPN01072 was calculated as described in the Dosimetry calculation procedure manual. Maximum value observed for each discernible organs across participants has been reported.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=11 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=6 Participants Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=9 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=10 Participants Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants n=36 Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Highest Absorbed Dose of 177LU-IPN01072 to Each Discernible Organ in Cycle 1 Spleen	8.07 Gray	6.00 Gray	5.90 Gray	4.09 Gray	8.07 Gray
Highest Absorbed Dose of 177LU-IPN01072 to Each Discernible Organ in Cycle 1 Bone marrow (image-based assay)	0.97 Gray	3.59 Gray	0.50 Gray	0.69 Gray	3.59 Gray
Highest Absorbed Dose of 177LU-IPN01072 to Each Discernible Organ in Cycle 1 Kidney (left + right)	8.55 Gray	4.87 Gray	5.86 Gray	5.07 Gray	8.55 Gray
Highest Absorbed Dose of 177LU-IPN01072 to Each Discernible Organ in Cycle 1 Liver	1.26 Gray	0.81 Gray	—	—	1.26 Gray

SECONDARY outcome

Timeframe: 4, 24, 48, 72 to 96 hours, 144 to 168 hours post infusion in Cycle 1

Population: The PP-DAS included all participants in the ITT-DAS for whom no major protocol violations occurred affecting dosimetry variables. Only data from the participants analyzed were reported.

The specific absorbed dose was evaluated centrally, using nuclear medicine images, as part of the dosimetry workflow. Data are presented for all lesions, regardless of their anatomical localization. The organs considered for 177Lu-IPN01072 image-based dosimetry assessment included: liver, bone marrow, kidney (left + right), and spleen. The specific absorbed dose to the lesions was the absorbed dose by the lesion (unit: Gray) divided by the injected radioactivity (unit: GBq) for each lesion selected for dosimetry evaluation. The specific absorbed dose for a given organ was the absorbed dose by this organ (unit: Gray) divided by the injected radioactivity (unit: GBq).

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=11 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=6 Participants Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=9 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=10 Participants Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants n=36 Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Specific Absorbed Dose Per Organ and Lesions of 177Lu-IPN01072 in Cycle 1 Lesions	2.56 Gray/GBq Interval 0.431 to 14.3	3.90 Gray/GBq Interval 1.92 to 83.3	6.82 Gray/GBq Interval 2.07 to 28.2	13.5 Gray/GBq Interval 2.2 to 81.0	5.00 Gray/GBq Interval 0.431 to 83.3
Specific Absorbed Dose Per Organ and Lesions of 177Lu-IPN01072 in Cycle 1 Bone marrow (image-based)	0.0796 Gray/GBq Interval 0.0431 to 0.216	0.135 Gray/GBq Interval 0.09 to 0.61	0.0850 Gray/GBq Interval 0.07 to 0.11	0.0650 Gray/GBq Interval 0.01 to 0.15	0.0900 Gray/GBq Interval 0.01 to 0.61
Specific Absorbed Dose Per Organ and Lesions of 177Lu-IPN01072 in Cycle 1 Kidney (left + right)	1.05 Gray/GBq Interval 0.522 to 1.85	0.720 Gray/GBq Interval 0.6 to 1.02	0.880 Gray/GBq Interval 0.46 to 1.18	0.765 Gray/GBq Interval 0.42 to 1.1	0.879 Gray/GBq Interval 0.42 to 1.85
Specific Absorbed Dose Per Organ and Lesions of 177Lu-IPN01072 in Cycle 1 Liver	0.186 Gray/GBq Interval 0.146 to 0.279	0.170 Gray/GBq Interval 0.17 to 0.17	—	—	0.179 Gray/GBq Interval 0.146 to 0.279
Specific Absorbed Dose Per Organ and Lesions of 177Lu-IPN01072 in Cycle 1 Spleen	0.769 Gray/GBq Interval 0.208 to 1.79	0.945 Gray/GBq Interval 0.5 to 1.08	0.985 Gray/GBq Interval 0.18 to 1.46	0.805 Gray/GBq Interval 0.36 to 0.98	0.840 Gray/GBq Interval 0.18 to 1.79

SECONDARY outcome

Timeframe: 4, 24, 48, 72 to 96 hours, 144 to 168 hours post infusion in Cycles 1 and 3

Population: The PP-DAS included all participants in the ITT-DAS for whom no major protocol violations occurred affecting dosimetry variables. Only data from the participants analyzed were reported.

The cumulative absorbed dose to the discernible organs (i.e., organs showing uptake) was evaluated centrally, using nuclear medicine images, as part of the dosimetry workflow.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=11 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=6 Participants Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=9 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=10 Participants Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants n=36 Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Cumulative Absorbed Organ Doses of 177Lu-IPN01072 in Cycles 1 and 3 Cycle 1: Bone marrow (image-based)	0.319 Gray Interval 0.102 to 0.974	0.715 Gray Interval 0.39 to 3.59	0.375 Gray Interval 0.26 to 0.5	0.285 Gray Interval 0.04 to 0.69	0.400 Gray Interval 0.04 to 3.59
Cumulative Absorbed Organ Doses of 177Lu-IPN01072 in Cycles 1 and 3 Cycle 1: Kidney (left + right)	4.31 Gray Interval 2.17 to 8.07	3.85 Gray Interval 3.36 to 4.58	3.25 Gray Interval 1.79 to 5.34	3.55 Gray Interval 1.74 to 4.88	3.73 Gray Interval 1.74 to 8.07
Cumulative Absorbed Organ Doses of 177Lu-IPN01072 in Cycles 1 and 3 Cycle 1: Liver	0.720 Gray Interval 0.336 to 1.26	0.810 Gray Interval 0.81 to 0.81	—	—	0.765 Gray Interval 0.336 to 1.26
Cumulative Absorbed Organ Doses of 177Lu-IPN01072 in Cycles 1 and 3 Cycle 1: Spleen	2.88 Gray Interval 0.844 to 8.07	4.35 Gray Interval 3.17 to 6.0	4.00 Gray Interval 0.71 to 5.9	3.55 Gray Interval 1.48 to 4.09	3.45 Gray Interval 0.71 to 8.07
Cumulative Absorbed Organ Doses of 177Lu-IPN01072 in Cycles 1 and 3 Cycle 3: Bone marrow (image-based)	1.11 Gray Interval 0.636 to 2.17	1.48 Gray Interval 1.48 to 1.48	1.09 Gray Interval 0.83 to 1.24	0.840 Gray Interval 0.29 to 1.23	1.10 Gray Interval 0.29 to 2.17
Cumulative Absorbed Organ Doses of 177Lu-IPN01072 in Cycles 1 and 3 Cycle 3: Kidney (left + right)	12.3 Gray Interval 7.67 to 24.1	9.41 Gray Interval 9.41 to 9.41	8.91 Gray Interval 6.29 to 14.0	10.1 Gray Interval 6.95 to 11.5	10.8 Gray Interval 6.29 to 24.1
Cumulative Absorbed Organ Doses of 177Lu-IPN01072 in Cycles 1 and 3 Cycle 3: Liver	2.08 Gray Interval 1.01 to 4.14	—	—	—	2.08 Gray Interval 1.01 to 4.14
Cumulative Absorbed Organ Doses of 177Lu-IPN01072 in Cycles 1 and 3 Cycle 3: Spleen	6.93 Gray Interval 4.99 to 15.6	7.58 Gray Interval 7.58 to 7.58	9.21 Gray Interval 2.82 to 14.6	8.08 Gray Interval 5.66 to 14.2	8.32 Gray Interval 2.82 to 15.6

SECONDARY outcome

Timeframe: 0 to 6 hours, 6 to 24 hours, 24 to 48 hours post-infusion in Cycle 1 of Part A; 0 to 4 hours, 4 to 24 hours, 24 to 48 hours in Cycle 1 of Part B.

Population: The Radiopharmaceutical PK Set (Part A and Part B) included all participants in the ITT set who received at least 1 dose of study medication and had at least 1 measured radioactive concentration in blood.

Urine was collected during the first 48 hours post infusion to determine the renal excretion of 177Lu-IPN01072 at Cycle 1 only.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=13 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=6 Participants Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=8 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=9 Participants Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants n=36 Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Cumulative Amount of Lu-177 Radioactivity Excreted Into the Urine (0 to 48 Hours) [Ae (0-48h)] in Cycle 1	2586 Mbq Interval 1722.0 to 4450.0	3106 Mbq Interval 2558.0 to 3998.0	2640 Mbq Interval 1346.0 to 3375.0	2621 Mbq Interval 471.0 to 3181.0	2787 Mbq Interval 471.0 to 4450.0

SECONDARY outcome

Timeframe: Pre-infusion (Baseline) and 5 minutes, 30 minutes, 60 minutes, 4 hours, 6 hours, 8 hours, 24 hours, 48 hours after the end of the infusion in Cycle 1

Population: The IPN01072 PK set in plasma (Part B only) included all participants in the ITT set who received at least 1 dose of study medication and have no major protocol deviations affecting the plasma PK variables and who had a sufficient number of plasma levels to estimate the main PK parameters. Only data from the participants analyzed were reported. Results were combined for IPN01072 PK analysis performed at cycle 1, as pre-specified according to study protocol and the data analysis plan.

The PK sampling was performed from Day 1 to Day 3 post infusion done at Cycle 1 for Part B only.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=16 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Time to Reach Maximum Plasma Concentration (Tmax) of IPN01072 in Cycle 1	0.083 hours Interval 0.0 to 0.28	—	—	—	—

SECONDARY outcome

Timeframe: Pre-infusion (Baseline) and 5 minutes, 30 minutes, 60 minutes, 4 hours, 6 hours, 8 hours, 24 hours, 48 hours after the end of the infusion in Cycle 1

Population: The IPN01072 PK set in plasma (Part B only) included all participants in the ITT set who received at least 1 dose of study medication and have no major protocol deviations affecting the plasma PK variables and who had a sufficient number of plasma levels to estimate the main PK parameters. Only data from the participants analyzed were reported. Results were combined for IPN01072 PK analysis performed at cycle 1, as pre-specified according to study protocol and the data analysis plan.

The PK sampling was performed from Day 1 to Day 3 post infusion done at Cycle 1 for Part B only.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=16 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Maximum Observed Plasma Concentration (Cmax) of IPN01072 in Cycle 1	10.7 nanogram (ng)/milliliter (mL) Standard Deviation 5.47	—	—	—	—

SECONDARY outcome

Timeframe: Pre-infusion (Baseline) and 5 minutes, 30 minutes, 60 minutes, 4 hours, 6 hours, 8 hours, 24 hours, 48 hours after the end of the infusion in Cycle 1

Population: The IPN01072 PK set in plasma (Part B only) included all participants in the ITT set who received at least 1 dose of study medication and have no major protocol deviations affecting the plasma PK variables and who had a sufficient number of plasma levels to estimate the main PK parameters. Only data from the participants analyzed were reported. Results were combined for IPN01072 PK analysis performed at cycle 1, as pre-specified according to study protocol and the data analysis plan.

The PK sampling was performed from Day 1 to Day 3 post infusion done at Cycle 1 for Part B only.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=15 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
AUC From Time Zero to Infinity (AUCinf) of IPN01072 in Cycle 1	45.8 ng*hour (h)/mL Standard Deviation 20.6	—	—	—	—

SECONDARY outcome

Timeframe: Pre-infusion (Baseline) and 5 minutes, 30 minutes, 60 minutes, 4 hours, 6 hours, 8 hours, 24 hours, 48 hours after the end of the infusion in Cycle 1

Population: The IPN01072 PK set in plasma (Part B only) included all participants in the ITT set who received at least 1 dose of study medication and have no major protocol deviations affecting the plasma PK variables and who had a sufficient number of plasma levels to estimate the main PK parameters. Only data from the participants analyzed were reported. Results were combined for IPN01072 PK analysis performed at cycle 1, as pre-specified according to study protocol and the data analysis plan.

The PK sampling was performed from Day 1 to Day 3 post infusion done at Cycle 1 for Part B only.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=15 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
T1/2 of IPN01072 in Cycle 1	6.09 hours Standard Deviation 1.59	—	—	—	—

SECONDARY outcome

Timeframe: Pre-infusion (Baseline) and 5 minutes, 30 minutes, 60 minutes, 4 hours, 6 hours, 8 hours, 24 hours, 48 hours after the end of the infusion in Cycle 1

Population: The IPN01072 PK set in plasma (Part B only) included all participants in the ITT set who received at least 1 dose of study medication and have no major protocol deviations affecting the plasma PK variables and who had a sufficient number of plasma levels to estimate the main PK parameters. Only data from the participants analyzed were reported. Results were combined for IPN01072 PK analysis performed at cycle 1, as pre-specified according to study protocol and the data analysis plan.

The PK sampling was performed from Day 1 to Day 3 post infusion done at Cycle 1 for Part B only.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=15 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Apparent Total Plasma Clearance of IPN01072 (Total CL) in Cycle 1	9.58 L/h Standard Deviation 12.8	—	—	—	—

SECONDARY outcome

Timeframe: Pre-infusion (Baseline) and 5 minutes, 30 minutes, 60 minutes, 4 hours, 6 hours, 8 hours, 24 hours, 48 hours after the end of the infusion in Cycle 1

Population: The IPN01072 PK set in plasma (Part B only) included all participants in the ITT set who received at least 1 dose of study medication and have no major protocol deviations affecting the plasma PK variables and who had a sufficient number of plasma levels to estimate the main PK parameters. Only data from the participants analyzed were reported. Results were combined for IPN01072 PK analysis performed at cycle 1, as pre-specified according to study protocol and the data analysis plan.

The PK sampling was performed from Day 1 to Day 3 post infusion done at Cycle 1 for Part B only.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=15 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Apparent Volume of Distribution During Terminal Phase (Vz) of IPN01072 in Cycle 1	68.7 Liter Standard Deviation 52.0	—	—	—	—

SECONDARY outcome

Timeframe: 0 to 4 hours, 4 to 24 hours, 24 to 48 hours in Cycle 1 of Part B

Population: The IPN01072 PK set in urine (Part B only) included all participants in the ITT set who received at least 1 dose of study medication and have no major protocol deviations affecting the urine PK variables and who had all urine IPN01072 levels to estimate the main urine PK parameters. Results were combined for IPN01072 PK analysis performed at cycle 1, as pre-specified according to study protocol and the data analysis plan.

Urine was collected during the first 48 hours post infusion to determine the renal excretion of 177Lu-IPN01072 at Cycle 1 for Part B only.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=23 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Ae (0-48h) of IPN01072 in Cycle 1	141 mcg Standard Deviation 65.9	—	—	—	—

SECONDARY outcome

Timeframe: 0 to 4 hours, 4 to 24 hours, 24 to 48 hours in Cycle 1 in Part B

Population: The IPN01072 PK set in urine (Part B only) included all participants in the ITT set who received at least 1 dose of study medication and had no major protocol deviations affecting the urine PK variables and who had all urine IPN01072 levels available to estimate the main urine PK parameters. Results were combined for IPN01072 PK analysis performed at cycle 1, as pre-specified according to study protocol and the data analysis plan.

Urine was collected during the first 48 hours post infusion to determine the renal excretion of 177Lu-IPN01072 at Cycle 1 for Part B only.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=23 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Fraction of IPN01072 Excreted Into the Urine (Fe) in Cycle 1	52.9 percentage of drug excreted into urine Standard Deviation 24.2	—	—	—	—

SECONDARY outcome

Timeframe: From the start of the first study medication (Cycle 1 Day 1) up to 2 years after the EOCT/death or lost to follow-up, maximum of 59 months.

Population: The ITT included all participants in the eligible participants set who received study medication.

The ORR was defined as the percentage of participants who achieved a complete response (CR) or a partial response (PR) as best overall response (BOR) according centralized to response evaluation criteria in solid tumours (RECIST) version 1.1 from investigator assessment. Participants with no tumour assessment after the start of study treatment were not evaluated. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 millimeter (mm). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=15 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=6 Participants Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=9 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=10 Participants Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants n=40 Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Overall Response Rate (ORR)	40.0 percentage of participants Interval 16.3 to 67.7	16.7 percentage of participants Interval 0.4 to 64.1	22.2 percentage of participants Interval 2.8 to 60.0	40.0 percentage of participants Interval 12.2 to 73.8	32.5 percentage of participants Interval 18.6 to 49.1

SECONDARY outcome

Timeframe: From the start of the first study medication (Cycle 1 Day 1) up to 2 years after the EOCT/death or lost to follow-up, maximum of 59 months.

Population: The ITT included all participants in the eligible participants set who received study medication.

The DCR was defined as the percentage of participants who achieved a CR, a PR or a stable disease (SD) as BOR according to Investigator assessment RECIST version 1.1 criteria. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=15 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=6 Participants Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=9 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=10 Participants Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants n=40 Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Disease Control Rate (DCR)	93.3 percentage of participants Interval 68.1 to 99.8	100.0 percentage of participants Interval 54.1 to 100.0	100.0 percentage of participants Interval 66.4 to 100.0	90.0 percentage of participants Interval 55.5 to 99.7	95.0 percentage of participants Interval 83.1 to 99.4

SECONDARY outcome

Timeframe: From the start of the first study medication (Cycle 1 Day 1) up to 2 years after the EOCT/death or lost to follow-up, maximum of 59 months.

Population: The ITT included all participants in the eligible participants set who received study medication.

The BOR according to RECIST v1.1 was defined as the best response recorded from the initiation of treatment until the EOCT/end of additional cycles (EOAC)/early withdrawal (EW) Visit (during the core study part), prior to the Investigator assessment of PD. Progression was defined as at least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=15 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=6 Participants Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=9 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=10 Participants Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants n=40 Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Best Overall Response PR	6 Participants	1 Participants	2 Participants	4 Participants	13 Participants
Best Overall Response SD	8 Participants	5 Participants	7 Participants	5 Participants	25 Participants
Best Overall Response PD	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Best Overall Response Not Evaluable (NE)	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants

SECONDARY outcome

Timeframe: From the start of the first study medication (Cycle 1 Day 1) up to 2 years after the EOCT/death or lost to follow-up, maximum of 59 months.

Population: The ITT included all participants in the eligible participants set who received study medication.

The PFS was defined as the time from start of study treatment until occurrence of tumour progression or death, according to Investigator assessment RECIST version 1.1. Estimation of the median was based on the Kaplan-Meier method.

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=6 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=3 Participants Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=6 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=5 Participants Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants n=20 Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Progression Free Survival (PFS)	29.7 months Interval 17.5 to NA indicates upper limit of confidence interval (CI) was not evaluable due to insufficient number of participants with events.	21.2 months Interval 19.4 to 22.4	25.1 months Interval 5.1 to NA indicates upper limit of CI was not evaluable due to insufficient number of participants with events.	11.1 months Interval 5.1 to NA indicates upper limit of CI was not evaluable due to insufficient number of participants with events.	28.1 months Interval 20.0 to NA indicates upper limit of CI was not evaluable due to insufficient number of participants with events.

SECONDARY outcome

Timeframe: Baseline (Day 1) and EOCT visit (30 months)

Population: The ITT included all participants in the eligible participants set who received study medication. Only data from the participants analyzed were reported.

The European Organisation for Research and Treatment of Cancer (EORTC) score questionnaire (QLQ-C30) was used for QoL evaluation. Each scale in the questionnaire were scored (0 to 100) according to the EORTC recommendations in the EORTC QLQ-C30 scoring manual. The scale included a global health status, where high score for the global health status represents a high QoL. The functional scales consisted of physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning, where a higher value reflects a better level of function. Nine symptoms scales included nausea and vomiting, pain, fatigue, dyspnoea, insomnia, appetite loss, constipation, diarrhoea and financial difficulties, where a higher value reflects worse symptoms. Baseline was defined as the last non-missing measurement collected prior to the first dose of study drug (Day 1).

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=13 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=1 Participants Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=8 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=4 Participants Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants n=26 Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Change From Baseline in Quality of Life (QoL) Questionnaire (QLQ)-C30 at EOCT Visit Global Health Status	1.27 score on a scale Standard Deviation 23.54	16.70 score on a scale Standard Deviation NA NA indicates that standard deviation could not be calculated as only 1 participant was analyzed.	-6.24 score on a scale Standard Deviation 14.61	29.15 score on a scale Standard Deviation 28.43	3.84 score on a scale Standard Deviation 23.83
Change From Baseline in Quality of Life (QoL) Questionnaire (QLQ)-C30 at EOCT Visit Physical functioning	-2.05 score on a scale Standard Deviation 11.03	0.00 score on a scale Standard Deviation NA NA indicates that standard deviation could not be calculated as only 1 participant was analyzed.	-0.82 score on a scale Standard Deviation 6.61	10.00 score on a scale Standard Deviation 20.00	0.26 score on a scale Standard Deviation 11.70
Change From Baseline in Quality of Life (QoL) Questionnaire (QLQ)-C30 at EOCT Visit Role functioning	3.85 score on a scale Standard Deviation 29.79	0.00 score on a scale Standard Deviation NA NA indicates that standard deviation could not be calculated as only 1 participant was analyzed.	-0.01 score on a scale Standard Deviation 19.90	12.50 score on a scale Standard Deviation 25.00	3.85 score on a scale Standard Deviation 25.08
Change From Baseline in Quality of Life (QoL) Questionnaire (QLQ)-C30 at EOCT Visit Emotional functioning	11.52 score on a scale Standard Deviation 30.15	-25.00 score on a scale Standard Deviation NA NA indicates that standard deviation could not be calculated as only 1 participant was analyzed.	-4.16 score on a scale Standard Deviation 7.74	10.43 score on a scale Standard Deviation 12.51	5.12 score on a scale Standard Deviation 23.70
Change From Baseline in Quality of Life (QoL) Questionnaire (QLQ)-C30 at EOCT Visit Cognitive functioning	6.41 score on a scale Standard Deviation 19.89	0.00 score on a scale Standard Deviation NA NA indicates that standard deviation could not be calculated as only 1 participant was analyzed.	-6.26 score on a scale Standard Deviation 12.43	12.50 score on a scale Standard Deviation 15.95	3.20 score on a scale Standard Deviation 17.66
Change From Baseline in Quality of Life (QoL) Questionnaire (QLQ)-C30 at EOCT Visit Social functioning	15.38 score on a scale Standard Deviation 33.65	0.00 score on a scale Standard Deviation NA NA indicates that standard deviation could not be calculated as only 1 participant was analyzed.	-2.09 score on a scale Standard Deviation 5.90	12.50 score on a scale Standard Deviation 25.00	8.97 score on a scale Standard Deviation 26.35

SECONDARY outcome

Timeframe: Baseline (Day 1) and EOCT visit (30 months)

Population: The ITT included all participants in the eligible participants set who received study medication. Only data from the participants analyzed were reported.

The GI.NET21 module was intended for use among participants with gastrointestinal related (GI.- related) neuroendocrine tumours, who vary in disease stage and treatments. The module comprises 21 questions, consisting of 5 scales (endocrine symptoms, G.I. symptoms, treatment related symptom, social function, disease related worries) and 4 single items that assessed muscle /bone pain symptom, sexual function, information/communication function, and body image. Each question was quoted from 1 (not at all) to 4 (very much). Each scale in the questionnaire was scored from 0 to 100. A higher value was equivalent to worse or more problems. Baseline was defined as the last non-missing measurement collected prior to the first dose of study drug (Day 1).

Outcome measures

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=13 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=1 Participants Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=8 Participants Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=4 Participants Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants n=26 Participants Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Change From Baseline in QLQ Gastro-intestinal. Neuroendocrine Tumour (GI.NET)21 at EOCT Visit Endocrine symptoms	-5.12 score on a scale Standard Deviation 13.31	11.10 score on a scale Standard Deviation NA NA indicates that standard deviation could not be calculated as only 1 participant was analyzed.	-0.00 score on a scale Standard Deviation 5.93	-5.55 score on a scale Standard Deviation 11.10	-2.98 score on a scale Standard Deviation 11.13
Change From Baseline in QLQ Gastro-intestinal. Neuroendocrine Tumour (GI.NET)21 at EOCT Visit G. I. symptoms	-3.58 score on a scale Standard Deviation 13.49	-6.70 score on a scale Standard Deviation NA NA indicates that standard deviation could not be calculated as only 1 participant was analyzed.	2.50 score on a scale Standard Deviation 7.04	-13.30 score on a scale Standard Deviation 17.22	-3.33 score on a scale Standard Deviation 12.81
Change From Baseline in QLQ Gastro-intestinal. Neuroendocrine Tumour (GI.NET)21 at EOCT Visit Treatment related symptom	5.62 score on a scale Standard Deviation 21.47	-6.70 score on a scale Standard Deviation NA NA indicates that standard deviation could not be calculated as only 1 participant was analyzed.	9.01 score on a scale Standard Deviation 15.11	-0.30 score on a scale Standard Deviation 8.15	5.28 score on a scale Standard Deviation 17.56
Change From Baseline in QLQ Gastro-intestinal. Neuroendocrine Tumour (GI.NET)21 at EOCT Visit Social function	-19.67 score on a scale Standard Deviation 15.83	-22.30 score on a scale Standard Deviation NA NA indicates that standard deviation could not be calculated as only 1 participant was analyzed.	-4.15 score on a scale Standard Deviation 8.29	-30.53 score on a scale Standard Deviation 5.55	-16.67 score on a scale Standard Deviation 15.17
Change From Baseline in QLQ Gastro-intestinal. Neuroendocrine Tumour (GI.NET)21 at EOCT Visit Disease related worries	-8.98 score on a scale Standard Deviation 14.63	-22.20 score on a scale Standard Deviation NA NA indicates that standard deviation could not be calculated as only 1 participant was analyzed.	3.46 score on a scale Standard Deviation 16.53	-18.05 score on a scale Standard Deviation 13.87	-7.06 score on a scale Standard Deviation 16.37

Adverse Events

Part A: 177Lu-IPN01072 4.5 GBq

Serious events: 2 serious events

Other events: 15 other events

Deaths: 2 deaths

Part B Cohort 1: 177Lu-IPN01072 6 GBq

Serious events: 1 serious events

Other events: 6 other events

Deaths: 0 deaths

Part B Cohort 3: 177Lu-IPN01072 4.5 GBq

Serious events: 2 serious events

Other events: 9 other events

Deaths: 0 deaths

Part B Cohort 6: 177Lu-IPN01072 4.5 GBq

Serious events: 3 serious events

Other events: 10 other events

Deaths: 1 deaths

All Participants

Serious events: 8 serious events

Other events: 39 other events

Deaths: 3 deaths

Serious adverse events

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=15 participants at risk Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=6 participants at risk Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=9 participants at risk Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=10 participants at risk Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants n=40 participants at risk Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Acute Myeloid Leukaemia	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	20.0% 2/10 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant Melanoma	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Precursor B-Lymphoblastic Lymphoma	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Asthenia	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Pyrexia	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Systemic Inflammatory Response Syndrome	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Nervous system disorders Presyncope	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Nervous system disorders Syncope	6.7% 1/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Cardiac disorders Tachycardia	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Abdominal Pain	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Injury, poisoning and procedural complications Ankle Fracture	6.7% 1/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations Tumour Marker Increased	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Musculoskeletal and connective tissue disorders Back Pain	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Vascular disorders Hypotension	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Myelodysplastic syndrome	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.

Other adverse events

Measure	Part A: 177Lu-IPN01072 4.5 GBq n=15 participants at risk Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg ±50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).	Part B Cohort 1: 177Lu-IPN01072 6 GBq n=6 participants at risk Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 3: 177Lu-IPN01072 4.5 GBq n=9 participants at risk Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	Part B Cohort 6: 177Lu-IPN01072 4.5 GBq n=10 participants at risk Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).	All Participants n=40 participants at risk Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).
Gastrointestinal disorders Nausea	80.0% 12/15 • Number of events 24 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	55.6% 5/9 • Number of events 13 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	80.0% 8/10 • Number of events 15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	65.0% 26/40 • Number of events 53 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Diarrhoea	53.3% 8/15 • Number of events 18 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	66.7% 6/9 • Number of events 14 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	60.0% 6/10 • Number of events 8 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	52.5% 21/40 • Number of events 41 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Vomiting	33.3% 5/15 • Number of events 8 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	44.4% 4/9 • Number of events 12 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	60.0% 6/10 • Number of events 9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	37.5% 15/40 • Number of events 29 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Abdominal Pain	33.3% 5/15 • Number of events 7 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	30.0% 3/10 • Number of events 4 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	25.0% 10/40 • Number of events 14 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Abdominal Pain Upper	33.3% 5/15 • Number of events 5 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	20.0% 2/10 • Number of events 5 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	20.0% 8/40 • Number of events 11 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Constipation	26.7% 4/15 • Number of events 4 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	15.0% 6/40 • Number of events 6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Dyspepsia	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	20.0% 2/10 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 4/40 • Number of events 4 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Flatulence	13.3% 2/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	7.5% 3/40 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Gastrointestinal Sounds Abnormal	13.3% 2/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	7.5% 3/40 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Gastrooesophageal Reflux Disease	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	20.0% 2/10 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	7.5% 3/40 • Number of events 4 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Abdominal Discomfort	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Abdominal Distension	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Dry Mouth	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Stomatitis	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Abdominal Pain Lower	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Abnormal Faeces	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Anorectal Discomfort	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Breath Odour	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Dental Caries	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Epigastric Discomfort	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Frequent Bowel Movements	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Gastrointestinal Motility Disorder	6.7% 1/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Gingival Bleeding	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Lip Dry	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Odynophagia	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Paraesthesia Oral	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Steatorrhoea	6.7% 1/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Gastrointestinal disorders Toothache	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Asthenia	20.0% 3/15 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	50.0% 3/6 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	22.2% 2/9 • Number of events 5 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	50.0% 5/10 • Number of events 11 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	32.5% 13/40 • Number of events 22 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Fatigue	60.0% 9/15 • Number of events 13 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	33.3% 3/9 • Number of events 6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	32.5% 13/40 • Number of events 20 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Feeling hot	13.3% 2/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Infusion site reaction	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	33.3% 2/6 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Malaise	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	20.0% 2/10 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Pyrexia	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Chest discomfort	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 5 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 5 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Chest pain	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Chills	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Discomfort	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Influenza like illness	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Injection site bruising	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Injection site reaction	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Injection site swelling	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Non-cardiac chest pain	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Oedema peripheral	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Pain	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Sense of oppression	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
General disorders Xerosis	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Skin and subcutaneous tissue disorders Alopecia	60.0% 9/15 • Number of events 14 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	33.3% 2/6 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	33.3% 3/9 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	50.0% 5/10 • Number of events 5 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	47.5% 19/40 • Number of events 24 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Skin and subcutaneous tissue disorders Dry skin	13.3% 2/15 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 4/40 • Number of events 5 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Skin and subcutaneous tissue disorders Rash	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 4/40 • Number of events 5 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Skin and subcutaneous tissue disorders Hyperhidrosis	13.3% 2/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	7.5% 3/40 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Skin and subcutaneous tissue disorders Pruritus	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	7.5% 3/40 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Skin and subcutaneous tissue disorders Onychoclasis	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Skin and subcutaneous tissue disorders Rash papular	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Skin and subcutaneous tissue disorders Urticaria	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Nervous system disorders Headache	33.3% 5/15 • Number of events 7 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	17.5% 7/40 • Number of events 11 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Nervous system disorders Dizziness	26.7% 4/15 • Number of events 5 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	15.0% 6/40 • Number of events 7 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Nervous system disorders Dysgeusia	13.3% 2/15 • Number of events 4 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	22.2% 2/9 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	12.5% 5/40 • Number of events 9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Nervous system disorders Lethargy	20.0% 3/15 • Number of events 8 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	7.5% 3/40 • Number of events 8 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Nervous system disorders Paraesthesia	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Nervous system disorders Parosmia	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	22.2% 2/9 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Nervous system disorders Syncope	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Nervous system disorders Taste disorder	13.3% 2/15 • Number of events 4 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 4 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Nervous system disorders Hypogeusia	6.7% 1/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Nervous system disorders Sensory disturbance	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Blood and lymphatic system disorders Thrombocytopenia	20.0% 3/15 • Number of events 10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	50.0% 3/6 • Number of events 13 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 4 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	20.0% 8/40 • Number of events 28 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Blood and lymphatic system disorders Neutropenia	13.3% 2/15 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	33.3% 2/6 • Number of events 6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	15.0% 6/40 • Number of events 13 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Blood and lymphatic system disorders Anaemia	20.0% 3/15 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	12.5% 5/40 • Number of events 6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Blood and lymphatic system disorders Lymphopenia	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	33.3% 2/6 • Number of events 10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	22.2% 2/9 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	12.5% 5/40 • Number of events 13 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Blood and lymphatic system disorders Leukopenia	13.3% 2/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 4 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 4/40 • Number of events 7 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Blood and lymphatic system disorders Lymph node pain	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Blood and lymphatic system disorders Myelosuppression	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Infections and infestations Nasopharyngitis	20.0% 3/15 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	22.2% 2/9 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	17.5% 7/40 • Number of events 7 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Infections and infestations Bronchitis	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	20.0% 2/10 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Infections and infestations Gastroenteritis	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Infections and infestations Sinusitis	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	20.0% 2/10 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Infections and infestations Upper respiratory tract infection	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Infections and infestations Anal fungal infection	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Infections and infestations Conjunctivitis	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Infections and infestations Cystitis	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Infections and infestations Groin abscess	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Infections and infestations Perineal infection	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Infections and infestations Pharyngitis	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Infections and infestations Tooth abscess	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Infections and infestations Tooth infection	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Infections and infestations Viral upper respiratory tract infection	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Vascular disorders Flushing	60.0% 9/15 • Number of events 13 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	22.2% 2/9 • Number of events 5 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	30.0% 12/40 • Number of events 21 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Vascular disorders Hot flush	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	30.0% 3/10 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 4/40 • Number of events 4 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Vascular disorders Hypotension	6.7% 1/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	22.2% 2/9 • Number of events 5 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	7.5% 3/40 • Number of events 7 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Vascular disorders Hypertension	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations Lymphocyte count decreased	20.0% 3/15 • Number of events 8 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	44.4% 4/9 • Number of events 14 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	17.5% 7/40 • Number of events 22 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations Platelet count decreased	6.7% 1/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	44.4% 4/9 • Number of events 11 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	12.5% 5/40 • Number of events 13 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations White blood cell count decreased	13.3% 2/15 • Number of events 5 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	22.2% 2/9 • Number of events 6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 4/40 • Number of events 11 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations C-reactive protein increased	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	7.5% 3/40 • Number of events 5 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations Blood urea increased	6.7% 1/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations Protein urine present	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 4 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 5 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations White blood cell count increased	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations Albumin urine present	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations Bilirubin urine present	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations Blood alkaline phosphatase increased	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations Blood creatinine increased	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations Blood potassium decreased	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations Blood potassium increased	6.7% 1/15 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations Blood pressure decreased	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations Cardiac murmur	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations Cortisol decreased	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations Creatinine renal clearance decreased	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations Electrocardiogram QT prolonged	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations Electrocardiogram ambulatory abnormal	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations Glomerular filtration rate decreased	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Investigations Liver function test increased	6.7% 1/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Musculoskeletal and connective tissue disorders Arthralgia	20.0% 3/15 • Number of events 5 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	22.2% 2/9 • Number of events 5 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	17.5% 7/40 • Number of events 13 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Musculoskeletal and connective tissue disorders Back pain	33.3% 5/15 • Number of events 6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	22.2% 2/9 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	17.5% 7/40 • Number of events 9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	13.3% 2/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	7.5% 3/40 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Musculoskeletal and connective tissue disorders Arthritis	13.3% 2/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Musculoskeletal and connective tissue disorders Groin pain	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	13.3% 2/15 • Number of events 4 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 4 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Musculoskeletal and connective tissue disorders Pain in extremity	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Musculoskeletal and connective tissue disorders Bone pain	6.7% 1/15 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Musculoskeletal and connective tissue disorders Coccydynia	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Musculoskeletal and connective tissue disorders Musculoskeletal stiffness	6.7% 1/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 4 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 4 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Musculoskeletal and connective tissue disorders Spinal pain	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Respiratory, thoracic and mediastinal disorders Cough	13.3% 2/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	7.5% 3/40 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Respiratory, thoracic and mediastinal disorders Dyspnoea	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	7.5% 3/40 • Number of events 5 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Respiratory, thoracic and mediastinal disorders Epistaxis	13.3% 2/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Respiratory, thoracic and mediastinal disorders Wheezing	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Respiratory, thoracic and mediastinal disorders Lung cyst	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Injury, poisoning and procedural complications Infusion related reaction	13.3% 2/15 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	7.5% 3/40 • Number of events 4 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Injury, poisoning and procedural complications Fall	13.3% 2/15 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Injury, poisoning and procedural complications Burn oesophageal	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Injury, poisoning and procedural complications Contusion	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Injury, poisoning and procedural complications Muscle strain	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Injury, poisoning and procedural complications Occupational exposure to radiation	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Cardiac disorders Tachycardia	13.3% 2/15 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	7.5% 3/40 • Number of events 5 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Cardiac disorders Palpitations	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Cardiac disorders Supraventricular extrasystoles	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Cardiac disorders Ventricular extrasystoles	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Cardiac disorders Arrhythmia	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Metabolism and nutrition disorders Decreased appetite	13.3% 2/15 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	30.0% 3/10 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	12.5% 5/40 • Number of events 6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Metabolism and nutrition disorders Hyperglycaemia	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Metabolism and nutrition disorders Increased appetite	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Psychiatric disorders Insomnia	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 2 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Psychiatric disorders Affective disorder	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	16.7% 1/6 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Psychiatric disorders Depressed mood	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Psychiatric disorders Sleep disorder	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Ear and labyrinth disorders Deafness neurosensory	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Ear and labyrinth disorders Deafness unilateral	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Ear and labyrinth disorders External ear pain	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Ear and labyrinth disorders Tinnitus	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Ear and labyrinth disorders Vestibular disorder	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Hepatobiliary disorders Hepatomegaly	13.3% 2/15 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	5.0% 2/40 • Number of events 3 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Hepatobiliary disorders Hepatic pain	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	11.1% 1/9 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Product Issues Product leakage	6.7% 1/15 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/10 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Renal and urinary disorders Microalbuminuria	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.
Reproductive system and breast disorders Ovarian Cyst	0.00% 0/15 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/6 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	0.00% 0/9 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	10.0% 1/10 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.	2.5% 1/40 • Number of events 1 • Treatment-emergent adverse events were collected from the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, a maximum of 33 months. The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.

Additional Information

Medical Director

Ipsen Pharma

Phone: see email

Email: clinical.trials@ipsen.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place

Restriction type: OTHER